Obstetric and Gynecologic Imaging

Why Is Routine Imaging Not Recommended for Asymptomatic Low-Risk Endometrial Cancer?

·
Why Is Routine Imaging Not Recommended for Asymptomatic Low-Risk Endometrial Cancer?

A 68-year-old patient, one year post-hysterectomy for FIGO Stage IA, Grade 1 endometrioid adenocarcinoma, is in your clinic for a routine follow-up visit. She feels well and has no new complaints. It’s tempting to order a surveillance CT scan “just to check,” providing reassurance for both patient and physician. However, for this specific clinical scenario—surveillance of an asymptomatic patient with treated low- or intermediate-risk endometrial cancer—is imaging the right choice? This article explores the evidence-based workflow and explains why the American College of Radiology (ACR) finds routine imaging studies, from ultrasound to CT, to be Usually not appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to asymptomatic patients who have completed definitive treatment for low- or intermediate-risk endometrial cancer. Clinically, this cohort typically includes patients with:

  • FIGO Stage I or II disease
  • Endometrioid histology, Grade 1 or 2
  • No or minimal myometrial invasion
  • No lymphovascular space invasion (LVSI)

The key qualifiers are asymptomatic and low- or intermediate-risk. This workflow should not be applied to patients who present with new symptoms or those with higher-risk disease features.

Exclusion Criteria (These Patients Follow a Different Workflow):

What Diagnoses Are You Working Up in This Scenario?

While routine imaging is not recommended, the goal of any surveillance strategy is the early detection of cancer recurrence. For low-risk endometrial cancer, understanding the patterns of recurrence explains why imaging has a low yield. The primary concern is identifying a recurrence before it becomes widely metastatic.

Vaginal Recurrence: This is the most common site of recurrence for early-stage endometrial cancer. These recurrences are typically located at the vaginal cuff (the top of the vagina after a hysterectomy). Crucially, they are often detected by a careful physical and pelvic examination or because they cause symptoms like spotting or discharge. Imaging has a limited role in screening for these superficial lesions in an asymptomatic patient.

Pelvic Nodal Recurrence: The cancer can recur in the lymph nodes within the pelvis. While cross-sectional imaging like CT or MRI can detect nodal disease, the incidence in this low-risk population is very low. The potential harms of routine imaging—false positives, radiation exposure, and cost—outweigh the small chance of finding an asymptomatic nodal recurrence.

Distant Metastasis: Less commonly, low-risk endometrial cancer can recur in distant sites such as the lungs, liver, or bone. These recurrences almost always become symptomatic, prompting a diagnostic workup. Screening an asymptomatic patient with whole-body imaging is not supported by evidence, as it rarely identifies these events earlier than symptoms do and does not demonstrably improve survival outcomes.

Why Is Routine Imaging ‘Usually Not Appropriate’ for This Presentation?

The ACR Appropriateness Criteria panel has concluded that for asymptomatic patients with treated low- or intermediate-risk endometrial cancer, all routine imaging modalities—including ultrasound, CT, and MRI—are Usually not appropriate. The rationale is multifaceted and rooted in the principles of evidence-based, high-value care.

The fundamental reason is the low pre-test probability of recurrence. In this specific patient population, the risk of recurrence is low, and studies have not shown that routine surveillance imaging improves overall survival or quality of life. Most recurrences (over 70%) in this group are detected because the patient develops symptoms, not because of a scheduled scan.

Furthermore, the potential for harm from routine imaging is significant. Incidental findings on CT or MRI are common and can lead to a cascade of further testing, patient anxiety, and increased healthcare costs, all without a clear clinical benefit. This low diagnostic yield means the number needed to scan to find one true, asymptomatic recurrence is prohibitively high.

Why Specific Modalities Are Not Recommended:

  • CT of the Chest, Abdomen, and Pelvis: While effective for detecting widespread disease, its use for routine surveillance exposes the patient to significant cumulative radiation (☢☢☢☢ 10-30 mSv per scan) without proven benefit. The risk of radiation-induced secondary malignancy, though small, is not zero and must be weighed against the very low likelihood of detecting a clinically meaningful, asymptomatic recurrence.
  • MRI of the Abdomen and Pelvis: MRI avoids ionizing radiation but is a costly and resource-intensive examination. Its high sensitivity can also lead to the detection of benign or indeterminate findings, triggering further unnecessary workups. Without clinical suspicion, its routine use is not justified.
  • Ultrasound (Pelvic or Abdominal): Ultrasound is non-invasive and uses no radiation, but it has poor sensitivity for detecting small-volume nodal or peritoneal recurrence. Its primary role is in evaluating symptomatic patients (e.g., for hydronephrosis from ureteral obstruction), not for asymptomatic screening.

What’s Next? The Recommended Surveillance Workflow

If imaging is not the answer, what is the standard of care for surveillance in this patient population? The focus shifts from radiological screening to a robust clinical follow-up strategy centered on patient history and physical examination.

If the patient remains asymptomatic: The recommended surveillance protocol, supported by organizations like the Society of Gynecologic Oncology (SGO), involves regular clinical visits. These visits should include:

  • A thorough review of systems, specifically asking about vaginal bleeding or spotting, pelvic or abdominal pain, persistent cough, or unexplained weight loss.
  • A physical examination, including a careful speculum and bimanual pelvic exam to assess the vaginal cuff and pelvis.

The frequency of these visits is typically every 3-6 months for the first 2-3 years, then decreasing to every 6-12 months thereafter, as the risk of recurrence diminishes over time.

If the patient develops symptoms: This is the critical trigger to change course. If a patient reports new, concerning symptoms (e.g., postmenopausal bleeding), they are no longer considered in a routine surveillance scenario. The next step is to initiate a diagnostic workup. This shifts the patient into the ACR scenario for clinically suspected recurrence, where imaging, such as CT or PET/CT, becomes appropriate to identify the location and extent of potential disease.

Pitfalls to Avoid (and When to Get Help)

The primary pitfall in this scenario is ordering surveillance imaging out of habit or for “reassurance” without a clear clinical indication. This can lead to a cascade of low-value care. Another common error is failing to educate the patient on the symptoms of recurrence; an informed patient is the most effective partner in surveillance. Do not dismiss vague symptoms; a low threshold to transition from a surveillance to a diagnostic mindset is crucial. If a patient develops any new symptom concerning for recurrence, particularly vaginal bleeding, the immediate next step is a thorough physical exam and consideration for diagnostic imaging and/or biopsy, often in consultation with a gynecologic oncologist.

Related ACR Topics and Tools

This article covers one specific variant within a broader topic. For a comprehensive overview of imaging across all related clinical presentations, from initial staging to the workup of high-risk or symptomatic patients, please see our parent guide. It provides a hub-and-spoke model to navigate the full ACR guidelines.

Frequently Asked Questions

Why is imaging recommended for high-risk endometrial cancer surveillance but not for low-risk?

The key difference is the pre-test probability of recurrence. Patients with high-risk features (e.g., high-grade tumors, deep invasion, certain histologies) have a significantly higher chance of recurrence, including asymptomatic distant metastases. In this group, the potential benefit of detecting an early, asymptomatic recurrence with imaging may outweigh the harms of radiation and false positives. For low-risk patients, the recurrence rate is so low that the harms of routine imaging are considered greater than the potential benefits.

If my low-risk patient is very anxious and insists on a scan, should I order one?

This is a common clinical challenge. The best approach is patient education and shared decision-making. Explain the evidence that routine scans do not improve survival in her situation and can lead to unnecessary tests and anxiety from false positives. Reiterate the importance of clinical follow-up and symptom awareness as the proven, effective surveillance strategy. Ordering a scan against guidelines for reassurance alone is generally considered low-value care.

Are there any blood tests, like CA-125, that should be used for surveillance instead of imaging?

The role of serum markers like CA-125 in routine surveillance for low-risk endometrial cancer is not well-established and is generally not recommended. While it may be elevated in some recurrences, it has low sensitivity and specificity in this setting. The standard of care remains focused on clinical history and physical examination.

What if a physical exam is difficult or limited, for example, in a patient with obesity?

While a limited physical exam can be a challenge, it does not automatically justify routine imaging in an asymptomatic, low-risk patient. The core rationale—that most recurrences present with symptoms and that imaging has a very low yield—still holds. The focus should remain on diligent symptom review and patient education. Imaging should be reserved for when symptoms or specific physical findings arise.

How long should clinical surveillance continue for these patients?

Most recurrences of endometrial cancer occur within the first three years after treatment. Surveillance is most intensive during this period (e.g., visits every 3-6 months). After 3-5 years, the risk drops significantly, and the frequency of follow-up visits can be reduced (e.g., annually). Many guidelines suggest that after 5 years with no evidence of disease, patients can return to routine annual care with their primary care provider or gynecologist, with continued emphasis on reporting any new symptoms.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026